
Opinion|Videos|March 4, 2025
Long-Term Use of Topical Treatments in Atopic Dermatitis
Author(s)Omar Noor, MD, FAAD, Randy Alevi, DO
Panelists discuss how the newer topical agents (PDE4 inhibitors, JAK inhibitors) demonstrate comparable efficacy to midpotency corticosteroids but with improved safety profiles, lacking steroid-related adverse effects such as skin atrophy, hypothalamic-pituitary-adrenal axis suppression, and tachyphylaxis when used long term.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do the long-term efficacy and safety profiles of these newer agents compare with topical corticosteroids?
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Centanafadine Granted FDA Priority Review for the Treatment of ADHD Across Pediatric and Adult Populations
2
FDA Approves Updated Prescribing Information for Inhaled Insulin Powder, Including New Starting Dose Guidance
3




































































































































